Compared with the general population, people with cancer have a higher risk of arterial thrombotic events such as stroke, myocardial infarction and peripheral arterial embolism. This risk has a potential to be further increased in females undergoing controlled ovarian hyperstimulation for<unk> , but is usually only associated with cases of ovarian hyperstimulation syndrome (OHSS). On the other hand, venous thromboembolism rarely occurs unless a pregnancy is achieved, and is therefore usually not particularly relevant in the stage of oocyte retrieval. Therefore, the recommended controlled ovarian hyperstimulation protocol for in females with cancer is an antagonist protocol using a GnRH agonist for final maturation induction, in order to decrease the risk of OHSS. When used in conjunction with oocyte or embryo cryopreservation, using GnRH agonist rather than hCG for final maturation induction has no evidence of a difference in live birth rate (in contrast to fresh cycles where usage of GnRH agonist has a lower live birth rate). Anticoagulant prophylaxis is recommended to be administered only to selected subgroups of females such as those with other risk factors of hypercoagulability or those who do develop early OHSS.
Fertility preservation
Fertility tourism
Semen cryopreservation
Assisted reproductive technology
Vas-occlusive contraception
Sex reassignment surgery 
Sex reassignment surgery
Intersex medical interventions